These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 35995830)

  • 21. SARS-CoV-2-specific Cell-mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19.
    Fernández-Ruiz M; Olea B; Giménez E; Laguna-Goya R; Trujillo H; Caravaca-Fontán F; Gutiérrez E; López-Medrano F; Remigia MJ; Almendro-Vazquez P; Polanco N; González E; Ruiz-Merlo T; Parra P; San Juan R; Andrés A; Navarro D; Aguado JM
    Transplantation; 2021 Jun; 105(6):1372-1380. PubMed ID: 33729741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of plasma IFN signaling-related miRNAs during acute SARS-CoV-2 infection and its association with RBD-IgG antibody response.
    Wu J; Liu X; Shao J; Zhang Y; Lu R; Xue H; Xu Y; Wang L; Zhou H; Yu L; Yue M; Dong C
    Virol J; 2021 Dec; 18(1):244. PubMed ID: 34876159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
    Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
    Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Existence of SARS-CoV-2 in COVID-19 Patients: Host Immunity, Viral Virulence, and Transmissibility.
    Wang X; Huang K; Jiang H; Hua L; Yu W; Ding D; Wang K; Li X; Zou Z; Jin M; Xu S
    Virol Sin; 2020 Dec; 35(6):793-802. PubMed ID: 33156486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robust spike-specific CD4
    Federico L; Tvedt THA; Gainullin M; Osen JR; Chaban V; Lund KP; Tietze L; Tran TT; Lund-Johansen F; Kared H; Lind A; Vaage JT; Stratford R; Tennøe S; Malone B; Clancy T; Myhre AEL; Gedde-Dahl T; Munthe LA
    Front Immunol; 2023; 14():1210899. PubMed ID: 37503339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents.
    Tsang HW; Chua GT; To KKW; Wong JSC; Tu W; Kwok JSY; Wong WHS; Wang X; Zhang Y; Rosa Duque JS; Chan GCF; Chu WK; Pang CP; Tam PKH; Lau YL; Wong ICK; Leung WH; Yuen KY; Kwan MYW; Ip P
    Front Immunol; 2021; 12():797919. PubMed ID: 34975908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4
    Coulon PG; Prakash S; Dhanushkodi NR; Srivastava R; Zayou L; Tifrea DF; Edwards RA; Figueroa CJ; Schubl SD; Hsieh L; Nesburn AB; Kuppermann BD; Bahraoui E; Vahed H; Gil D; Jones TM; Ulmer JB; BenMohamed L
    Front Immunol; 2024; 15():1343716. PubMed ID: 38605956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spike protein is a key target for stronger and more persistent T-cell responses-a study of mild and asymptomatic SARS-CoV-2 infection.
    Ssali I; Mugaba S; Watelo AK; Bemanzi J; Katende JS; Oluka GK; Ankunda V; Baine C; Kato L; ; Onyachi N; Muwanga M; Jjuuko M; Kayiwa J; Nsereko C; Auma BO; Weiskopf D; Sette A; Lutalo T; Musenero M; Kaleebu P; Serwanga J
    Int J Infect Dis; 2023 Nov; 136():49-56. PubMed ID: 37683720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of changes in immune status linked to COVID-19 convalescent and its clinical severity in patients and uninfected exposed relatives.
    Torres Rives B; Zúñiga Rosales Y; Mataran Valdés M; Roblejo Balbuena H; Martínez Téllez G; Rodríguez Pérez J; Caridad Marín Padrón L; Rodríguez Pelier C; Sotomayor Lugo F; Valdés Zayas A; Carmenate Portilla T; Sánchez Ramírez B; Carlos Silva Aycaguer L; Portal Miranda JA; Marcheco Teruel B
    Immunobiology; 2022 May; 227(3):152216. PubMed ID: 35436751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
    Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X
    Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term SARS-CoV-2-specific cellular immunity after COVID-19 in liver transplant recipients.
    Citores MJ; Caballero-Marcos A; Cuervas-Mons V; Alonso-Fernández R; Graus-Morales J; Arias-Milla A; Valerio M; Muñoz P; Salcedo M
    J Microbiol Immunol Infect; 2023 Jun; 56(3):526-536. PubMed ID: 36964052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
    Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
    Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
    Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
    Front Immunol; 2021; 12():684014. PubMed ID: 34194438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Response to SARS-CoV-2 Vaccine in 2 Men.
    Gupta S; Su H; Agrawal S
    Int Arch Allergy Immunol; 2022; 183(3):350-359. PubMed ID: 34794147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Highly Specific Assay for the Detection of SARS-CoV-2-Reactive CD4
    Zelba H; Worbs D; Harter J; Pieper N; Kyzirakos-Feger C; Kayser S; Seibold M; Bartsch O; Ködding J; Biskup S
    J Immunol; 2021 Feb; 206(3):580-587. PubMed ID: 33298615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T cell immune response predicts survival in severely ill COVID-19 patients requiring venovenous extracorporeal membrane oxygenation support.
    Ulakcsai Z; Szabo L; Szabo Z; Karaszi E; Szabo T; Fazekas L; Vereb A; Kovacs NF; Nemeth D; Kovacs E; Nemeth E; Nagy G; Vago H; Merkely B
    Front Immunol; 2023; 14():1179620. PubMed ID: 37600824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens.
    Rezaei M; Sadeghi M; Korourian A; Tabarsi P; Porabdollah M; Askari E; Mortaz E; Mahmoudi S; Marjani M; Velayati AA
    Hum Antibodies; 2021; 29(2):109-113. PubMed ID: 33720878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4
    Aiello A; Coppola A; Vanini V; Petrone L; Cuzzi G; Salmi A; Altera AMG; Tortorella C; Gualano G; Gasperini C; Scolieri P; Beccacece A; Vita S; Bruzzese V; Lorenzetti R; Palmieri F; Nicastri E; Goletti D
    Int J Infect Dis; 2022 Sep; 122():841-849. PubMed ID: 35878802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
    Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
    Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study.
    Molodtsov IA; Kegeles E; Mitin AN; Mityaeva O; Musatova OE; Panova AE; Pashenkov MV; Peshkova IO; Alsalloum A; Asaad W; Budikhina AS; Deryabin AS; Dolzhikova IV; Filimonova IN; Gracheva AN; Ivanova OI; Kizilova A; Komogorova VV; Komova A; Kompantseva NI; Kucheryavykh E; Lagutkin DА; Lomakin YA; Maleeva AV; Maryukhnich EV; Mohammad A; Murugin VV; Murugina NE; Navoikova A; Nikonova MF; Ovchinnikova LA; Panarina Y; Pinegina NV; Potashnikova DM; Romanova EV; Saidova AA; Sakr N; Samoilova AG; Serdyuk Y; Shakirova NT; Sharova NI; Sheetikov SA; Shemetova AF; Shevkova LV; Shpektor AV; Trufanova A; Tvorogova AV; Ukrainskaya VM; Vinokurov AS; Vorobyeva DA; Zornikova KV; Efimov GA; Khaitov MR; Kofiadi IA; Komissarov AA; Logunov DY; Naigovzina NB; Rubtsov YP; Vasilyeva IA; Volchkov P; Vasilieva E
    Clin Infect Dis; 2022 Aug; 75(1):e1-e9. PubMed ID: 35435222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.